-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Ligand Pharmaceuticals Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Ligand Pharmaceuticals Inc Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$13.5M, a 1630% decline year-over-year.
- Ligand Pharmaceuticals Inc Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $10.9M, a 79.9% decline year-over-year.
- Ligand Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2023 was $9.84M, a 76.1% decline from 2022.
- Ligand Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2022 was $41.2M.
- Ligand Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2021 was -$4.15M, a 21.8% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)